Top

Published in:

01-07-2017 | Original Article

Gastric tumours in FAP

Authors: Sarah-Jane Walton, Ian M. Frayling, Susan K. Clark, Andrew Latchford

Published in: Familial Cancer | Issue 3/2017

Abstract

Gastric cancer is not a recognised extra-colonic manifestation of FAP, except in countries with a high prevalence of gastric cancer. Data regarding gastric adenomas in FAP are sparse. The aim of this study was to review the clinical characteristics of gastric tumours occurring within an FAP population from the largest European polyposis registry. All patients that developed a gastric adenoma or carcinoma were identified from a prospectively maintained registry database. The primary outcome measure was the occurrence of gastric adenoma or adenocarcinoma. Secondary outcomes included APC mutation, tumour stage, management and survival. Eight patients developed gastric cancer and 21 an adenoma (median age 52 and 44 years, respectively). Regular oesophagogastroduodenoscopy surveillance was performed in 6/8 patients who developed cancer. Half were advanced T3/4 tumours and 6/8 had nodal or metastatic spread at diagnosis. All cancer cases died within a median of 13.5 months from diagnosis. Gastric adenomas were evenly distributed: 11/21 (52%) in the distal and 10/21 (48%) proximal stomach, whereas 5/8 (63%) cancers were located proximally. An association between gastric tumour and desmoid development was observed; 7/8 (88%) cancer and 11/21 (52%) adenoma cases had a personal or family history of desmoid. It would appear from this small, retrospective study that gastric cancer is not a prominent extra-colonic feature of FAP in the Western world. It seems to present at an advanced stage with a poor prognosis. There may be an association between gastric tumour and desmoid occurrence but a large multicentre cohort is necessary to investigate this further.

Bisgaard ML, Fenger K, Bulow S, Niebuhr E, Mohr J (1994) Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat 3:121–125CrossRefPubMed

Arvanitis ML, Jagelman DG, Fazio VW, Lavery IC, McGannon E (1990) Mortality in patients with familial adenomatous polyposis. Dis Colon Rectum 33:639–642CrossRefPubMed

Bertario L, Presciuttini S, Sala P, Rossetti C, Pietroiusti M (1994) Causes of death and postsurgical survival in familial adenomatous polyposis: results from the Italian Registry. Italian Registry of Familial Polyposis Writing Committee. Semin Surg Oncol 10:225–234CrossRefPubMed

Offerhaus GJ, Giardiello FM, Krush AJ, Booker SV, Tersmette AC, Kelley NC, Hamilton SR (1992) The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology 102:1980–1982CrossRefPubMed

Garrean S, Hering J, Saied A, Jani J, Espat NJ (2008) Gastric Adenocarcinoma Arising from Fundic Gland Polyps in a Patient with Familial Adenomatous Polyposis Syndrome. Am Surg 74:79–83PubMed

Wood LD, Salaria SN, Cruise MW, Giardiello FM, Montgomery EA (2014) Upper GI tract lesions in familial adenomatous polyposis (FAP): enrichment of pyloric gland adenomas and other gastric and duodenal neoplasms. Am J Surg Pathol 38:389–393CrossRefPubMedPubMedCentral

Park JG, Park KJ, Ahn YO, Song IS, Choi KW, Moon HY, Choo SY, Kim JP (1992) Risk of gastric cancer among Korean familial adenomatous polyposis patients. Report of three cases. Dis Colon Rectum 35:996–998CrossRefPubMed

Iwama T, Mishima Y, Utsunomiya J (1993) The impact of familial adenomatous polyposis on the tumorigenesis and mortality at the several organs. Its rational treatment. Ann Surg 217:101–108CrossRefPubMedPubMedCentral

Utsunomiya J, Miki Y, Kuroki T, Furuyama J (1988) Recent trends in studies on carcinogenesis in familial adenomatous polyposis. Gan To Kagaku Ryoho 15:185–191PubMed

10.

Shibata C, Ogawa H, Miura K, Naitoh T, Yamauchi J, Unno M (2013) Clinical characteristics of gastric cancer in patients with familial adenomatous polyposis. Tohoku J Exp Med 229:143–146CrossRefPubMed

11.

Sarre RG, Frost AG, Jagelman DG, Petras RE, Sivak MV, McGannon E (1987) Gastric and duodenal polyps in familial adenomatous polyposis: a prospective study of the nature and prevalence of upper gastrointestinal polyps. Gut 28:306–314CrossRefPubMedPubMedCentral

12.

Bianchi LK, Burke CA, Bennett AE, Lopez R, Hasson H, Church JM (2008) Fundic gland polyp dysplasia is common in familial adenomatous polyposis. Clin Gastroenterol Hepatol 6:180–185CrossRefPubMed

13.

Ngamruengphong S, Boardman LA, Heigh RI, Krishna M, Roberts ME, Riegert-Johnson DL (2014). Gastric adenomas in familial adenomatous polyposis are common, but subtle, and have a benign course. Hered Cancer Clin Pract 12:4CrossRefPubMedPubMedCentral

14.

Park SY, Ryu JK, Park JH, Yoon H, Kim JY, Yoon YB, Park JG, Lee SH, Kang SB, Park JW et al (2011) Prevalence of gastric and duodenal polyps and risk factors for duodenal neoplasm in korean patients with familial adenomatous polyposis. Gut Liver 5:46–51CrossRefPubMedPubMedCentral

15.

Iida M, Yao T, Itoh H, Watanabe H, Matsui T, Iwashita A, Fujishima M (1988) Natural history of gastric adenomas in patients with familial adenomatosis coli/Gardner’s syndrome. Cancer 61:605–611CrossRefPubMed

16.

Nakamura S, Matsumoto T, Kobori Y, Iida M (2002) Impact of Helicobacter pylori infection and mucosal atrophy on gastric lesions in patients with familial adenomatous polyposis. Gut 51:485–489CrossRefPubMedPubMedCentral

17.

Yamaguchi T, Ishida H, Ueno H, Kobayashi H, Hinoi T, Inoue Y, Ishida F, Kanemitsu Y, Konishi T, Tomita N et al (2016) Upper gastrointestinal tumours in Japanese familial adenomatous polyposis patients. Jpn J Clin Oncol 46:310–315CrossRefPubMedPubMedCentral

18.

Spigelman AD, Williams CB, Talbot IC, Domizio P, Phillips RK (1989) Upper gastrointestinal cancer in patients with familial adenomatous polyposis. The Lancet 2:783–785CrossRef

19.

Fearnhead NS, Britton MP, Bodmer WF (2001) The ABC of APC. Hum Mol Genet 10:721–733CrossRefPubMed

20.

Lamlum H, Ilyas M, Rowan A, Clark S, Johnson V, Bell J, Frayling I, Efstathiou J, Pack K, Payne S et al (1999) The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson’s ‘two-hit’ hypothesis. Nat Med 5:1071–1075CrossRefPubMed

21.

Crabtree M, Sieber OM, Lipton L, Hodgson SV, Lamlum H, Thomas HJ, Neale K, Phillips RK, Heinimann K, Tomlinson IP (2003) Refining the relation between ‘first hits’ and ‘second hits’ at the APC locus: the ‘loose fit’ model and evidence for differences in somatic mutation spectra among patients. Oncogene 22:4257–4265CrossRefPubMed

22.

Groves C, Lamlum H, Crabtree M, Williamson J, Taylor C, Bass S, Cuthbert-Heavens D, Hodgson S, Phillips R, Tomlinson I (2002) Mutation cluster region, association between germline and somatic mutations and genotype-phenotype correlation in upper gastrointestinal familial adenomatous polyposis. Am J Pathol 160:2055–2061CrossRefPubMedPubMedCentral

23.

Sinha A, Tekkis PP, Gibbons DC, Phillips RK, Clark SK (2011) Risk factors predicting desmoid occurrence in patients with familial adenomatous polyposis: a meta-analysis. Colorectal Dis 13:1222–1229CrossRefPubMed

24.

Pimenta-Melo AR, Monteiro-Soares M, Libanio D, Dinis-Ribeiro M (2016). Missing rate for gastric cancer during upper gastrointestinal endoscopy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol

25.

Vasen HF, Moslein G, Alonso A, Aretz S, Bernstein I, Bertario L, Blanco I, Bulow S, Burn J, Capella G et al (2008) Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 57:704–713CrossRefPubMed

26.

Church J, Xhaja X, LaGuardia L, O’Malley M, Burke C, Kalady M (2015) Desmoids and genotype in familial adenomatous polyposis. Dis Colon Rectum 58:444–448CrossRefPubMed

27.

Komatsu S, Ichikawa D, Kurioka H, Koide K, Ueshima Y, Shioaki Y, Lee CJ, Mutoh F, Hosokawa Y, Oka T et al (2006) Intra-abdominal desmoid tumor mimicking lymph node recurrence after gastrectomy for gastric cancer. J Gastroenterol Hepatol 21:1224–1226CrossRefPubMed

28.

Kim PS, Han DS, Han HS, Bang HY (2014) Intra-abdominal fibromatosis after gastrectomy for gastric cancer. Ann Surg Treat Res 87:331–335CrossRefPubMedPubMedCentral

Title: Gastric tumours in FAP
Authors: Sarah-Jane Walton
Ian M. Frayling
Susan K. Clark
Andrew Latchford
Publication date: 01-07-2017
Publisher: Springer Netherlands
Published in: Familial Cancer / Issue 3/2017
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-017-9966-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2017

The association between prognosis of breast cancer and first-degree family history of breast or ovarian cancer: a systematic review and meta-analysis

Supporting disclosure of genetic information to family members: professional practice and timelines in cancer genetics

Biallelic BRCA2 mutations in two black South African children with Fanconi anaemia

Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?

Detection of false positive mutations in BRCA gene by next generation sequencing

Outcomes of retesting BRCA negative patients using multigene panels

Keynote webinar | Spotlight on antibody–drug conjugates in cancer